|
Item 1.01
|
Entry into a Material Definitive Agreement
|
On April 6, 2017, Amarantus BioScience Holdings,
Inc. (the “Company”) issued a 12% Senior Secured Convertible Note (the “Secured Note”) to Xpress Group
International Limited (the “Investor”) in the principal amount of $100,000 pursuant to a Securities Purchase Agreement
dated April 6, 2017 (the “SPA”).
The Secured Note matures on October 6, 2017
(the “Maturity Date”) and shall accrue interest at a rate equal to 12% per annum. The Secured Note contains certain
customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder or a material
breach of any transaction document. Upon the occurrence of any such Event of Default the outstanding principal amount of the Secured
Note, plus accrued but unpaid interest and other amounts owing in respect thereof through the date of acceleration, shall become
immediately due and payable.
The Secured Note is convertible at any time
into either Company common stock at a fixed conversion price of $0.0125 per share or common shares of Avant Diagnostics, Inc. (“Avant”)
owned by the Company at a conversion price of $0.16 per share. If the market price of Avant common stock based on an average of
the closing trading price of Avant common stock for the five trading days immediately prior to the Conversion Date (the “Avant
Conversion Market Price”) was less than $0.32, then the Investors shall receive additional shares of Avant common stock such
that the total amount of Avant common stock received by the Investors as of the conversion date, when valued at the Avant Conversion
Market Price, will equal the conversion amount up to a maximum total of 5.5 million shares of Avant common stock.
On the Maturity Date, all outstanding principal
and accrued and unpaid interest shall be converted into Company common stock.
In addition, on April 6, 2017 the Company entered
into the Second Amendment To Intercreditor And Subordination Agreement (“Second Amendment”), by and among the, the
Company, all of the subsidiaries of the Company (such subsidiaries, the “Subsidiaries”, the Company jointly and severally,
together with their respective successors and assigns, collectively, the “Debtors”), GEMG LLC (“GEMG”),
Anson Investments Master Fund LP (“Anson”), Dominion Capital, LLC, (“Dominion”) and Delafield Investments
Limited (“Delafield”) the holders (Anson, Dominion and Delafield are collectively, the “April 2016 Holders”)
of the Company’s 12% Senior Secured Convertible Promissory Notes, in the original aggregate principal amount of approximately
$9,215,000 pursuant to the Senior Loan Agreement, Delafield in its capacity as collateral agent (in such capacity, the “Collateral
Agent”) and the Investor pursuant to which the Secured Note and any subsequent amounts invested by the Investor in the Company
in the form of a secured note shall be subject to Second Amendment.
Additionally the Company entered into Amendment
No. 1 to the pledge agreement dated as of October 31, 2016 between the Company and the Investor (the “Pledge Agreement Amendment”)
pursuant to which the Company’s obligation under the Secured Note are secured by 5.5 million shares of Avant common stock
owned by the Company.
The Investor is a corporation owned by Mr.
Chan Heng Fai. Mr. Chan is also the owner of Amarantus Bioscience PTE, Ltd., the controlling shareholder of the Company. In addition,
Mr. Chan is the Chief Executive Officer of Singapore eDevelopment Limited. Pursuant to a non-binding Letter of Intent entered into
in February of 2017 between the Company and SeD Biomedical Inc., a subsidiary of Singapore eDevelopment Limited, wherein SeD Biomedical
Inc. agreed to inject certain assets into the Company, subject to certain contingencies, including, but not limited to, the completion
of due diligence and the execution of definitive agreements. Pursuant to the non-binding Letter of Intent, SeD Biomedical is entitled
to select certain members of the Company’s Board of Directors, and has named four of the Company’s current eight directors.
Those directors named by SED BioMedical Inc. recused themselves from all deliberations regarding the Secured Note, the SPA, the
Second Amendment and the Pledge Agreement Amendment.
The foregoing summaries of the Secured Note,
SPA, Second Amendment, the Pledge Agreement Amendment and the Convertible Notes do not purport to be complete and are qualified
in their entirety by reference to the copies of the Secured Note, SPA, Second Amendment, the Pledge Agreement Amendment and the
Convertible Notes filed as exhibits hereto.